HC Wainwright Issues Pessimistic Outlook for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Monday, May 4th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.57) for the quarter, down from their prior estimate of ($0.42). HC Wainwright currently has a “Buy” rating and a $88.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.13 EPS and FY2026 earnings at ($0.57) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million.

TARS has been the subject of several other research reports. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. Guggenheim increased their target price on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $90.67.

Tarsus Pharmaceuticals Stock Up 0.7%

Shares of NASDAQ:TARS opened at $65.04 on Wednesday. The firm has a market cap of $2.80 billion, a P/E ratio of -40.15 and a beta of 0.52. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $85.25. The business has a fifty day simple moving average of $69.03 and a 200 day simple moving average of $72.00. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of TARS. TimesSquare Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals during the third quarter worth about $15,898,000. Jennison Associates LLC increased its position in shares of Tarsus Pharmaceuticals by 5.5% during the third quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after acquiring an additional 136,582 shares during the last quarter. Citigroup Inc. increased its position in shares of Tarsus Pharmaceuticals by 78.1% during the 3rd quarter. Citigroup Inc. now owns 40,591 shares of the company’s stock valued at $2,412,000 after purchasing an additional 17,797 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Tarsus Pharmaceuticals by 77.0% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 91,590 shares of the company’s stock worth $5,443,000 after buying an additional 39,838 shares during the last quarter. Finally, Artisan Partners Limited Partnership increased its holdings in Tarsus Pharmaceuticals by 3.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 558,326 shares of the company’s stock worth $33,181,000 after acquiring an additional 19,023 shares during the period. Institutional investors own 90.01% of the company’s stock.

Insider Transactions at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $283,477.00. Following the completion of the sale, the general counsel directly owned 63,959 shares of the company’s stock, valued at $4,285,253. The trade was a 6.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Elizabeth Yeu Lin sold 390 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $26,130.00. Following the transaction, the insider directly owned 23,308 shares in the company, valued at approximately $1,561,636. This trade represents a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 79,391 shares of company stock valued at $5,432,035. 8.97% of the stock is owned by insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.